Close menu




August 2nd, 2022 | 10:57 CEST

These sources of return concern us all: Fresenius, Defence Therapeutics, BioNTech

  • Biotechnology
Photo credits: pixabay.com

When people receive an unexpected diagnosis or a loved one suddenly dies, our health suddenly becomes very important. Even though there is often no room for such topics in the daily lives of investors, it is worthwhile to deal with health for several reasons. On the one hand, preventive care brings the most important of all returns; on the other hand, this rather unpleasant topic in everyday life also holds opportunities if we focus on health risks and look at possible solutions. We present three stocks from the healthcare sector that deserve attention.

time to read: 3 minutes | Author: Nico Popp
ISIN: FRESENIUS SE+CO.KGAA O.N. | DE0005785604 , DEFENCE THERAPEUTICS INC | CA24463V1013 , BIONTECH SE SPON. ADRS 1 | US09075V1026

Table of contents:


    Fresenius: What is going on?

    The current share price of dialysis specialist Fresenius is a tragedy: In the past ten years, the share price has not been as low as it is today. If a stock split is also considered, the share is valued much lower today than it was back then. The weaker result at the beginning of the year was due to burdens in the wake of the pandemic. Fresenius is currently doing particularly well with the Helios hospital chain, which has significantly increased its sales in recent months. Investors in Fresenius always benefit indirectly from the business of its subsidiary Fresenius Medical Care - here, sales rose by 8% at the beginning of the year. But why is the Fresenius share not getting off the ground?

    The debt ratio at Fresenius is currently around 60% - and rising. In times of rising interest rates, investors are therefore becoming cautious. Although the Company wants to become significantly more profitable by the end of next year and save around EUR 150 million annually, this information has been known on the market for some time now, without investors having bought into it when the share price was falling. With another pandemic fall looming, Fresenius' "covid-sensitive" stock does not appear to be a good choice. However, the stable dividend, which currently offers a yield of more than 3%, is a positive factor.

    Defence Therapeutics: Renowned institutes pave the way for approval procedures starting in 2023

    Defence Therapeutics does not pay a dividend. However, a payout is the last thing investors expect from the Canadian biotech company. Defence Therapeutics has several mainstays and works, among other things, on vaccines against cancer, such as skin or breast cancer. The Company's own patented drug enhancer Accum™ has potential as an active ingredient in addition to its intrinsic property, as it is highly toxic and is said to offer potential in tumors when applied in a targeted manner. A few weeks ago, the Company announced plans to further research the technology in collaboration with internationally renowned institutes such as the Curie Institute, the Institut de Recherche en Cancérologie de Montpellier and the HUS Comprehensive Cancer Center from Finland. These collaborations with different foci and experts could yield important insights for Defence.

    In early 2023, Defence Therapeutics plans to launch as many as three Phase 1 trials to drive regulatory approval of its technology. "Defence's Accum™ platform was primarily developed and tested in vitro and in vivo to improve intranuclear drug delivery for several FDA-approved antibody conjugates or novel conjugates in development. We strongly believe that all these important results achieved this year related to Accum™ ADCs will further demonstrate the efficacy of our Accum™ technology and take Defence to a new level," said Sebastien Plouffe, CEO of Defence Therapeutics. After falling significantly in recent weeks, the stock could become interesting again as we head into winter. In June, Canadian analyst firm Canaccord Genuity published detailed research on the Company. Defence Therapeutics should therefore be on several watch lists.

    BioNTech: Legal dispute leaves the market cold

    With fall approaching, BioNTech's stock is also worth a look. The Corona vaccine pioneer is currently working on improved versions of its vaccine for the fall. At the same time, the patent dispute with Tübingen-based rival CureVac entered a new round. BioNTech has defended itself in the US with a declaratory judgment action and assumes that it has not infringed any patents held by the Swabians. Even though legal disputes never go down well on the market, as a rule, the share has recently freed itself and is now at the upper end of the sideways trend that has been intact since the turn of the year. If new impulses follow, BioNTech can quickly head back toward EUR 200. However, investors should be aware that new highs are rather unlikely for BioNTech.


    If you consciously leave everyday life behind and focus on health risks, you will quickly realize how important innovative companies from the pharmaceutical and biotech sectors are. While the Fresenius share offers little perspective for the reasons mentioned, BioNTech appears to be on the rise despite being a dividend aristocrat. Defence Therapeutics could also offer great opportunities due to its low valuation and the numerous prospects surrounding its patented Accum™ technology.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 22nd, 2023 | 06:50 CEST

    Cardiol Therapeutics, BioNTech, BYD - At top speed to new markets

    • Biotechnology
    • Pharma
    • Electromobility

    Cardiol Therapeutics is enjoying a remarkable development. The biotech company is now rolling out its ARCHER patient recruitment trial internationally at 35 participating centers. This accelerates research in the development of their therapy to combat myocarditis, a heart inflammation which has been associated with COVID-19 vaccination. For Cardiol Therapeutics, this represents an opportunity to get its therapy approved as an orphan drug. Approval is also at stake for BioNTech. With a multimillion-dollar funding boost, the Company is working on accelerated approval for a vaccine against a virus that caused quite a stir last year. The shortened development time is likely to impress investors. While business nations agree on fighting viruses, they disagree on commodities for the road. The EU would prefer to restrict BYD's successful sales on domestic roads - by imposing tariffs. BYD, meanwhile, is tapping into a completely different market.

    Read

    Commented by André Will-Laudien on September 18th, 2023 | 06:30 CEST

    Unbelievable! Hands off AI, biotech in rebound! Bayer, Defence Therapeutics, Morphosys

    • AI
    • Biotechnology
    • Investments

    The big fall decline is now over. It is always a difficult time, but the so-called "Triple Witching" went relatively smoothly this time. The European Central Bank (ECB), in its first interest rate meeting after the summer break, decided to raise key rates by another quarter point to 4.00%, up from the previous 3.75% in July. At the same time, it lowered its inflation forecast for 2025 and the outlook for economic growth in the Eurozone for the years 2023 to 2025. Economic risks are increasing, but inflation remains the determining factor for interest rates. Expectations that the US Federal Reserve (FED) will announce an interest rate pause at its next meeting on Wednesday have boosted confidence. Last week's big losers were the recently favoured AI stocks Nvidia, Microsoft and C3.ai. However, the biotech sector has recently started to climb again. Where are the opportunities for investors?

    Read

    Commented by Nico Popp on September 13th, 2023 | 08:30 CEST

    Biotech: Poison cocktail or miracle cure? Defence Therapeutics, MorphoSys, Pfizer

    • Biotechnology
    • Pharma

    Biotech stocks represent both light and dark. At the end of 2020, BioNtech turned the tide of the pandemic with its Comirnaty vaccine. But many shareholders have also had to endure losses. An example of a loss-maker is the share of the SDAX stock MorphoSys. Between 2020 and 2022, the share lost more than 80%. But what were the reasons for the decline? Are there biotech companies that offer better prospects? We shed light on three stocks from the biotech and healthcare sectors.

    Read